# Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

> **NCT06504290** · PHASE1 · RECRUITING · sponsor: **Vigonvita Life Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** VV119 Placebo （in healthy adult subjects）
- **DRUG:** VV119 （in healthy adult subjects）
- **DRUG:** VV119(in adult patients with schizophrenia)
- **DRUG:** VV119 Placebo （in adult patients with schizophrenia）

## Key facts

- **NCT ID:** NCT06504290
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504290, "Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06504290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*